These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 15521896

  • 1. Adsorption of oxacalcitriol by polysulphone haemodialyser in patients with secondary hyperparathyroidism.
    Tsuruoka S, Yamamoto H, Ioka T, Ando H, Saito T, Fujimura A.
    Br J Clin Pharmacol; 2004 Nov; 58(5):488-95. PubMed ID: 15521896
    [Abstract] [Full Text] [Related]

  • 2. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
    Murakami K, Miyachi H, Watanabe A, Kawamura N, Fujii M, Koide S, Murase M, Kushimoto H, Hasegawa M, Tomita M, Hiki Y, Sugiyama S.
    Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study.
    Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E.
    Nephrol Dial Transplant; 1996 Nov; 11 Suppl 3():121-4. PubMed ID: 8840326
    [Abstract] [Full Text] [Related]

  • 5. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 6. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH.
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [Abstract] [Full Text] [Related]

  • 7. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V, Andreini B, De Pietro S, Migliori M, Taccola D, Giovannini L, Ferdeghini M, Palla R.
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [Abstract] [Full Text] [Related]

  • 8. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.
    Akizawa T, Ohashi Y, Akiba T, Suzuki M, Nishizawa Y, Ogata E, Slatopolsky E, Kurokawa K.
    Ther Apher Dial; 2004 Dec; 8(6):480-91. PubMed ID: 15663548
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012 Dec; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 11. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group.
    Frazao JM, Chesney RW, Coburn JW.
    Nephrol Dial Transplant; 1998 Dec; 13 Suppl 3():68-72. PubMed ID: 9568825
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients.
    Hamada C, Hayashi K, Shou I, Inaba M, Ro Y, Io H, Maeda K, Fukui M, Tomino Y.
    Perit Dial Int; 2005 Dec; 25(6):570-5. PubMed ID: 16411524
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Dec; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 15. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
    Grekas D, Balaskas E, Kampouris H, Benos A, Konstantinou A, Sioullis A, Tourkantonis A.
    Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
    [Abstract] [Full Text] [Related]

  • 16. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S, Wazny LD, Martin JE.
    Can J Clin Pharmacol; 2008 Sep; 15(1):e36-43. PubMed ID: 18192704
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients].
    Kasai K, Abe R, Wakabayashi M, Nakamura K, Sawatani S, Wakabayashi T.
    Nihon Jinzo Gakkai Shi; 2002 Sep; 44(5):464-70. PubMed ID: 12216479
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S.
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.